Eli Lilly, type 2 diabetes
Eli Lilly Say Most Tirzepatide Users Remained Diabetes-Free at 176 Weeks
Eli Lilly said new results from a Phase 3 study of its tirzepatide showed weekly injections in adults with pre-diabetes and obesity or overweight resulted in sustained weight loss, with nearly 99% remaining diabetes-free at 176 weeks.
Eli Lilly said on Monday it sued three medical spas and online vendors for selling products that claimed to contain tirzepatide, the main ingredient in its popular weight-loss medicine ...
The headline trial results will be closely monitored by pharmaceutical industry experts. Shares in Novo Nordisk, which ...
For many patients on tirzepatide, a transformative medication used for weight loss and diabetes, the end of the drug's shortage ... A spokesperson for Eli Lilly told CBS News that "all doses ...
New research shows that weight loss medications can stop the progression of prediabetes. Experts don’t all agree on such a ...
The drugmaker has received approval from the Hong Kong government to sell its tirzepatide injections — branded as Mounjaro — ...
Eli Lilly claims there is no evidence that this compounded drug is safe and effective; the FDA has not approved an oral version of tirzepatide. MangoRx said it “has strong arguments against ...
Following an impressive data drop this summer highlighting the potential for Eli Lilly’s tirzepatide to stave off progression ...
Amgen Inc.'s stock dropped over 7% on Tuesday following revelations about bone density loss in early trials of its ...
Eli Lilly (NYSE: LLY) sells a broad range of pharmaceuticals treating various diseases, but one portfolio in particular has ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback